Recent progress in medicinal chemistry of D4 agonists.
In the last decades, the physiological and pharmacological properties of dopamine receptors were controversial principally because of the lack of selective ligand for some receptor subtypes. Since 1997, some specific D4 agonists have been described and have allowed a therapeutic approach. We report here, compounds described as D4 agonist and when available the SAR. The major studies for physiological implications and their potential biological applications are also reported and principally their interest in erectile dysfunction.
Enguehard-Gueiffier
Cécile
C
Department of Medicinal Chemistry, SPOT EA3857, Faculty of Pharmacy, 31 Avenue Monge, 37200 Tours, France. gueiffier@univ-tours.fr
Gueiffier
Alain
A
D000818:Animals; D018491:Dopamine Agonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D015195:Drug Design; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010879:Piperazines / Q000737:chemistry*; D010880:Piperidines / Q000737:chemistry*; D050638:Receptors, Dopamine D4 / Q000145:classification / Q000187:drug effects* / Q000378:metabolism; D013329:Structure-Activity Relationship
D018491:Dopamine Agonists; D010879:Piperazines; D010880:Piperidines; D050638:Receptors, Dopamine D4